Page 127

Febrero 2017

caso cl ínico 263 Referencias 1. Emery P, Fleischmann R, Filipowicz-Sosnowska A, Schechtman J, Szczepanski L, Kavanaugh A, et al. The efficacy and safety of rituximab in patients with active rheumatoid arthritis despite methotrexate treatment: results of a phase IIB randomized, double-blind, placebo controlled, dose ranging trial. Arthritis Rheum 2006; 54 (5): 1390-400. 2. O’Brien S, Kantarjian H, Thomas D, Giles F, Freireich E, Cortés J, et al. M. Rituximab dose-escalation trial in chronic lymphocytic leukemia. J Clin Oncol 2001; 19: 2165-70. 3. Plosker GL, Figgit DP. Rituximab: a review of its use in nonhodgkin’s lymphoma and chronic lymphocytic leukaemia. Drugs 2003; 63: 803-43. 4. Ghielmini M, Schimtz S, Burki K, Pichert G, Betticher D, Stupp R, et al. The effect of rituximab on patients with follicular and mantle-cell lymphoma. Ann Oncol 2000; 11: S123-6. 5. Bugelski P, Achuthanandam R, Capocasale R, Treacy G, Bouman-Thio E. Monoplano antibody-induced cytokine release syndrome. Expert Rev Clin Immunol 2009; 5 (5): 499-521. 6. Kunkel L, Wong A, Maneatis T, Nickas J, Brown T, Grillo-López A, et al. Optimizing the use of rituximab for treatment of B-cell non-Hodgkin’s lymphoma: a benefit-risk update. Semin Oncol 2000; 27: 53-61. 7. Millward P, Bandarenko N, Chang P, Stagg K, Afenyi Annan A, Hay S, et al. Cardiogenic shock complicates successful treatment of refractory thrombotic thrombocytopenia purpura with Rituximab. Transfusion 2005; 45: 1481-86. 8. Wu SJ, Chou WC, Ko BS, Tien HF: Severe pulmonary complications after initial treatment with Rituximab for the Asian-variant of intravascular lymphoma. Haematologica 2007; 92: 141-2. 9. Gutiérrez A, Rodríguez J, Martínez J, Amezaga R, Ramos R, Galmes B, et al. Pathogenic study of anti-CD20 infusion-related severe refractory shock in diffuse large B-cell lymphoma. Leukemia & Lymphoma 2006; 47 (1): 111-5. 10. Makino K, Nakata J, Kawachi S, Hayashi T, Nakajima A, Yokoyama M. Treatment strategy for reducing the risk of rituximab-induced cytokine release syndrome in patients with intravascular large B-cell lymphoma: a case report and review of the literature. J Med Case Rep 2013; 7: 280. Rituximab y shock en vasculitis - E. Palma et al Rev Med Chile 2017; 145: 260-263


Febrero 2017
To see the actual publication please follow the link above